Drug intelligence / Profile preview

Gubiao Fanggan

Development stage: Preclinical
Lead developer: First Affiliated Hospital of Hunan University of Chinese Medicine
Administration: Oral

Overview

Gubiao Fanggan is a Traditional Chinese Medicine (TCM) herbal formulation developed as a granule for the treatment of patients in the recovery phase of COVID-19. It is specifically indicated for individuals diagnosed with lung-spleen qi deficiency syndrome according to TCM principles. The formulation is designed to consolidate the exterior and tonify qi, which translates to strengthening the body's immune defenses and improving systemic vitality to alleviate lingering symptoms and prevent secondary infections. The drug is being evaluated in clinical trials sponsored by the Affiliated Hospital of Hu'nan Academy of Traditional Chinese Medicine.

Other names: Gubiao Fanggan granuleGubiao Fanggan Keli

Beyond the preview

Go deeper on Gubiao Fanggan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gubiao Fanggan.

Explore the full profile